Abiomed's percutaneous heart pump clears Health Canada
Abiomed, a developer of heart support technologies, has received Health Canada approval to market the Impella cVAD device, a percutaneous Impella heart pump.

The Impella cVAD1 is designed to provide temporary circulatory support via a catheter-based pump that is inserted percutaneously. cVAD seeks to provide peak flow of approximately four liters of blood per minute, according to the Danvers, Mass.-based company.

The Impella cVAD is not currently cleared for sale or use in the U.S.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup